 Zai Lab Limited NASDAQ: ZLAB and Blueprint Medicines Corporation NASDAQ: BPMC have announced an exclusive collaboration and license agreement in Greater China, including mainland China, Hong Kong, Macau, and Taiwan. The agreement covers the development and commercialization of BLU-945 and BLU-701 for epidermal growth factor receptor EGFR-driven non-small cell lung cancer. 